BioStock: PHI’s new CEO: “I am excited to lead us forward with new energy”

November 6, 2024
Language flag

Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. We spoke with him about his vision for the future.

Read the full interview with Anders Månsson on biostock.se.

What are your top priorities for the company in the first six months as CEO?

My initial impression is that we need to prioritize the development of a clinically applicable product while we more optimally manage the sales process for our existing products together with our commercial partner, Altium. Also, we need to make PHI a great place to work. Doing all of this right will generate shareholder value!

Anders Månsson, CEO

Related press release

PHI appoints Anders Månsson as new CEO

The board of Phase Holographic Imaging (PHI) has today appointed Anders Månsson as the new CEO of PHI as of November 1, 2024. The current CEO, Patrik Eschricht, will remain in his role until November 1, 2024, and ensure a smooth handover to Anders Månsson.

Latest News

Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ)

Phase Holographic Imaging PHI AB (publ) held its annual general meeting on 31 October 2024. The following resolutions were made.

PHI secures a loan from Altium SA

Phase Holographic Imaging PHI AB (“PHI”) announces that the Company has been provided a loan of SEK 7 million from the main shareholder Altium SA. PHI and Altium SA are also in dialogues regarding long-term financing of PHI.

PHI AB’s warrant exercise registered at the Swedish Companies Registration Office

Phase Holographic Imaging PHI AB (“PHI” or “Company”) today announces that the new shares from the exercise of warrants of series TO 4 have been registered at the Swedish Companies Registration Office.
See All News